ALK-Abelló A/S

ALK is a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies.

ALK specialises in allergy vaccination – a unique treatment that not only reduces symptoms but also treats the underlying cause of the allergy.

ALK offers allergy vaccination products in the form of injections and tablets, with the tablets being the latest, most well-documented and simplest form of treatment. In addition, ALK offers products for the treatment of severe allergic reactions (anaphylaxis) as well as products for allergy diagnostics.

The company has its headquarters in Hørsholm, north of Copenhagen, and employs around 2,700 people all over the world. ALK is listed on NASDAQ Copenhagen.

Since 2005, the Lundbeck Foundation has owned 40% of the shares (67% of the voting rights).